TopoTarget

CuraGen Sells 5 Million TopoTarget Shares for Approximately $12 Million

BRANFORD, Conn., May 22 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ) announced today the completion of a series of privately negotiated transactions in which the Company sold the 5,000,000 shares of TopoTarget common stock issued to the Company as partial payment for the sale...

CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA

- Conference call to be hosted on Tuesday, December 11th at 9:00 a.m. Eastern time - - Encouraging clinical results presented at ASH from the ongoing Phase II trial in T-cell lymphomas - - Positive End-of-Phase II meeting held with the FDA for b...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

...s into Tekmira Pharmaceuticals II-50 MilleGen Enters into Collaboration with LFB II-50 Access Pharmaceuticals to Acquire Somanta II-50 topotarget to Acquire Apoxis SA II-51 Genentech Inks Exclusive Global Licensing Agreement with Seattle Genetics II-51 Celgene Agrees to Acquisition o...

CuraGen Reports First Quarter 2008 Financial Results

...March 31, 2008, CuraGen had cash, restricted cash and investments of approximately $107.4 million. Following this morning's announced transaction with topotarget A/S, CuraGen currently projects a total of approximately $145 million in cash, restricted cash and investments at April 30, 2008. CuraGen has also r...

TopoTarget in Medical Technology

CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting

BRANFORD, Conn., Nov. 26 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today that updated preliminary clinical trial results from the Phase II study ...

CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference

- Significant anti-tumor activity of combination IV belinostat in ovarian cancer reported - - Oral belinostat demonstrated to be safe and well-tolerated in Phase I - - Presentation of results from two NCI-sponsored clinical trials - - CuraGen to provide a clinical up...

CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia

BRANFORD, Conn., Aug. 28 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase I/II clinical trial evaluating belinostat (PXD101), a histone deacetylase (HDAC) inhibitor, i...

CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings

BRANFORD, Conn., April 19, 2007 /PRNewswire-FirstCall/ -- CuraGen Corporation and TopoTarget A/S announced today that preliminary interim clinical data on intravenous belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, are expected to be pres...

CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE

..., during the same period in 2007. Significant one time transactions during the second quarter of 2008 included the sale of the rights to belinostat to topotarget A/S for approximately $38 million in cash and the repurchase of $50.9 million of debt for $43.2 million in privately negotiated transactions. As of ...

TopoTarget in Biological News

Massey researchers induce cell death in leukemia

...h, interactions between bortezomib and romidepsin (Gloucester Pharmaceuticals) and bortezomib with belinostat (aka PXD101 from CuraGen Corporation and topotarget A/S), were examined in human CLL cells isolated from five patients. Bortezomib dramatically potentiated the lethality of both agents in cells from fou...

TopoTarget in Biological Technology

CuraGen Sells Ownership of Belinostat to TopoTarget A/S

- CuraGen to receive approximately $45 million in cash, stock and future milestone payments - - Provides updated financial guidance for 2008 - - Conference call to be hosted today at 9:00 a.m. EDT - BRANFORD, Conn., April 22 /PRNewswire-FirstCall/ -- ...

CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma

BRANFORD, Conn., Dec. 19 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase II open-label, multi-center ...

Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL

...in combination chemotherapy regimens. In May 2005, topotarget announced the signing of a Cooperative Research an...ormation for clinical trials. About TopoTarget topotarget (OMX: TOPO) is an international biotech company he... mTOR, FasLigand and topoisomerase II inhibitors). topotarget has a broad cllinical pipeline with 9 products in ...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...OMX Nordic Exchange Stockholm: QMED) SYNERON MEDICAL LTD (NASDAQ: ELOS ) topotarget A/S (OMX Nordic Exchange Copenhagen: TOPO) TORAY INDS INC (Tokyo SE: 3402)... THERAPEUTICS (NASDAQ: NKTR ) PROTHERICS (London Main Market, U.K.: PTI) topotarget A/S (OMX Nordic Exchange Copenhagen: TOPO) TRANSGENE (Euronext, Paris: TNG...

TopoTarget Successfully Buys Back Full Control of Belinostat

... the Global Rights for the Product topotarget Acquires US & RoW Rights From CuraGen Corporation ... million (DKK 122.8 million), a Total of 5 Million topotarget Shares and a Commercial Milestone Payment - Webcast Conference Call to be Held 2pm CET topotarget A/S (OMX: TOPO) today announced that the company h...